These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11580212)

  • 1. Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content.
    Dolman C; Thorpe SJ; Thorpe R
    Biologicals; 2001 Jun; 29(2):75-9. PubMed ID: 11580212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
    Rodeghiero F
    Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia.
    Cooper N
    Hematol Oncol Clin North Am; 2009 Dec; 23(6):1317-27. PubMed ID: 19932436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy.
    Simpson KN; Coughlin CM; Eron J; Bussel JB
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):58-64. PubMed ID: 9523750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura.
    Kumar M; Vik TA; Johnson CS; Southwood ME; Croop JM
    Am J Hematol; 2005 Mar; 78(3):181-7. PubMed ID: 15726607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-Rh(D): an efficacious therapeutic alternative in autoimmune hemocytopenias].
    Mascarin M; Trovò MG; Ventura A
    Pediatr Med Chir; 1993; 15(4):349-52. PubMed ID: 8265453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children.
    Freiberg A; Mauger D
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):23-7. PubMed ID: 9523746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-D: mechanisms of action.
    Ware RE; Zimmerman SA
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):14-22. PubMed ID: 9523745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura.
    Ramadan KM; El-Agnaf M
    Clin Lab Haematol; 2005 Aug; 27(4):267-9. PubMed ID: 16048495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura.
    Kane I; Ragucci D; Shatat IF; Bussel J; Kalpatthi R
    Br J Haematol; 2010 Apr; 149(1):79-83. PubMed ID: 20096011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?
    Crow AR; Lazarus AH
    Transfus Med Rev; 2008 Apr; 22(2):103-16. PubMed ID: 18353251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of adult idiopathic thrombocytopenic purpura.
    Nakhoul IN; Kozuch P; Varma M
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):136-44, 153. PubMed ID: 16728922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins.
    Mehta YS; Badakere SS
    J Postgrad Med; 1996; 42(2):46-9. PubMed ID: 9715299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics of therapy for ITP: steroids, i.v.Ig, anti-D, and splenectomy.
    Adams JR; Nathan DP; Bennett CL
    Blood Rev; 2002 Mar; 16(1):65-7. PubMed ID: 11913999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of IVIG and anti-D in ITP.
    Lazarus AH; Crow AR
    Transfus Apher Sci; 2003 Jun; 28(3):249-55. PubMed ID: 12725951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura.
    Scaradavou A; Bussel JB
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):52-7. PubMed ID: 9523749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
    Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH
    J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.
    Tremblay T; Paré I; Bazin R
    Transfusion; 2013 Feb; 53(2):261-9. PubMed ID: 22670706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune complexes as therapy for autoimmunity.
    Clynes R
    J Clin Invest; 2005 Jan; 115(1):25-7. PubMed ID: 15630438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The successful treatment of idiopathic thrombocytopenic purpura with the low dose non specific IgG component of anti D immunoglobulin.
    Smith NA; Chakraverty RK; Boughton BJ
    Clin Lab Haematol; 1990; 12(2):131-6. PubMed ID: 2119931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.